Skip to main content
Caplight Logo









Baxiva AG

Baxiva AG

Private
SchlierenHealthcare & Life Scienceshttps://www.baxiva.com/

Last Round

Accelerator

Feb 23, 2026

Total Funding Raised

$3.19M

Company Overview

Baxiva AG is a biotechnology company that develops next-generation glycoconjugate vaccines to prevent serious infections caused by Gram-negative bacteria.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

glycoconjugate vaccinebiotechnologyvaccine platformdrug discoveryextraintestinal pathogenic Escherichia coliExPECGram-negative bacteriabiotech startupvaccine developmentnanoparticle carrierantimicrobial resistancebiotech licensingpharma partneringwet labpreclinical research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Baxiva AG Comparables

Compare Baxiva AG with similar companies based on industry and business-model similarity.

Baxiva AG comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Omniose
83%
Glycovax Pharma
81%
Matrivax Research & Development Corporation
78%

Baxiva AG Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorFeb 23, 2026
GrantAug 22, 2025

Key People

Founding team and executive leadership

Tim Keys

Chief Executive Officer

Executive Team

Johannes K. Mühl

Chief Operating Officer

Executive Team

Baxiva AG Investors

Notable investors and investment history

Baxiva AG investors
InvestorRounds
CARB-XGrant
Venture KickAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 3, 2026

    Monthly visitors increased 69% MoM, reaching 1.4K.

  • Mar 3, 2026

    Monthly visitors grew 2090% MoM, from 39 to 854.

Recent news

Latest coverage and updates

  • attends_eventJun 23, 2026

    Baxiva US$3M attended event 2026 Venture Awards on Jun 15th '26.

  • recognized_asJun 16, 2026

    Baxiva US$3M recognized as first place in their respective categories at Venture awards on Jun 15th '26.

Baxiva AG Filings

Explore SEC and related filing metadata, where available.

Baxiva AG filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Baxiva AG's valuation, stock price, and market status.

Is Baxiva AG a public or private company?

Baxiva AG is a private company.

What is the current stock price of Baxiva AG?

Baxiva AG is a private company with no public stock price. No recent secondary market data is available.

How much is Baxiva AG worth (valuation)?

Valuation information for Baxiva AG is not publicly available.

Can I buy Baxiva AG stock?

Baxiva AG shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Baxiva AG's last funding round?

Baxiva AG's most recent funding round was Accelerator on February 23, 2026.

Who are the main investors in Baxiva AG?

Key investors in Baxiva AG include CARB-X, Venture Kick.

Will Baxiva AG IPO soon?

No public IPO plans have been announced for Baxiva AG.

How can I track Baxiva AG secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Baxiva AG's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSchlieren
Employee Range7
Year Founded2025
Last FundingFeb 23, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?